Amedisys Price Performance
AMED opened at $93.68 on Monday. The stock has a 50-day moving average price of $94.52 and a 200-day moving average price of $93.47. Amedisys has a 12-month low of $69.36 and a 12-month high of $106.01. The company has a current ratio of 1.00, a quick ratio of 1.00 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $3.06 billion, a P/E ratio of 1,338.29, a PEG ratio of 2.12 and a beta of 0.86.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on Amedisys in a report on Monday. They issued a “buy” rating for the company. Eight investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $103.22.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of AMED. BlackRock Inc. grew its stake in shares of Amedisys by 3.7% in the 1st quarter. BlackRock Inc. now owns 3,896,785 shares of the health services provider’s stock worth $671,378,000 after buying an additional 138,484 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Amedisys by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,042,027 shares of the health services provider’s stock worth $294,438,000 after buying an additional 10,457 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Amedisys by 13.5% in the 1st quarter. JPMorgan Chase & Co. now owns 1,997,030 shares of the health services provider’s stock worth $146,881,000 after buying an additional 237,160 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Amedisys by 3.5% in the 1st quarter. Wellington Management Group LLP now owns 1,875,274 shares of the health services provider’s stock worth $323,092,000 after buying an additional 62,863 shares during the last quarter. Finally, Mackenzie Financial Corp grew its stake in shares of Amedisys by 3.8% in the 4th quarter. Mackenzie Financial Corp now owns 1,041,142 shares of the health services provider’s stock worth $86,977,000 after buying an additional 38,517 shares during the last quarter. Institutional investors own 95.70% of the company’s stock.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
- Five stocks we like better than Amedisys
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Uber quadruples EPS estimates, but is growth decelerating?
- How to Use the MarketBeat Dividend Calculator
- 3 stocks set to benefit from record Valentine’s Day spending
- What is a Dividend King?
- Tradeweb is a disruptive pure play on financial market liquidity
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.